AI Stroke Imaging Platform Significantly Reduces Initial Decision Time for Proper Treatment with Michalis Papadakis Brainomix

Michalis Papadakis, CEO and Co-Founder of Brainomix, is developing AI technology to automate the analysis of brain scans of stroke patients, addressing the critical clinical gap where a majority of patients who should receive treatment are not being identified. The platform identifies stroke location, blocked vessels, and at-risk brain tissue on CT scans, enabling faster diagnosis and treatment decisions by a broader range of front-line clinicians who may lack stroke care expertise. In a large-scale evaluation, Brainomix demonstrated that it can save an hour in reaching treatment decisions and dramatically increase the number of patients who achieve full recovery.

Michalis explains, "Brainomix started quite a few years ago now, and, as you noted, I'm one of the founders. And back then, I was the scientific director of the preclinical stroke lab at the University of Oxford here in the UK, doing research in stroke. And together with the other founders, what made us establish Brainomix and create Brainomix as a spinoff from the university was starting with the clinical unmet need.

"As we were all experts in stroke, we knew that stroke is a devastating disease. It takes the brain by 3.6 years every hour a patient remains untreated. And although we have lifesaving treatments, up to 80% of patients who should be treated are missing out. And when we created Brainomix, we knew that imaging, which means the interpretation of the brain scan of patients who have strokes, is a barrier that is leading directly to this big number of patients missing out on being selected for treatment."

"The idea was that if we used the AI and automated the analysis of the brain scans of those patients, we could help frontline clinicians with diagnosis and treatment decisions. So, since we started, we have been developing a technology that aims to increase the uptake of existing treatments in clinical care, but we are also working with pharma companies and biotech companies that are developing new treatments to increase the success of the trials."

#Brainomix #Brainomix360Stroke #StrokeCare #AcuteStroke #StrokeTreatment #Neurology #MedicalImaging #ImagingAI #AIinHealthcare #DigitialHealth #HealthcareInnovation #Neuroradiology #PatientOutcomes #Thrombectomy #DigitalHealth #ClinicalDecisionSupport

brainomix.com

Download the transcript here